Back to mobile site

More on CADL

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-166.7% Growth)
- Ratings (9.2 Score)

Upcoming Events

- Earnings (8/19/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Candel Therapeutics (NQ:CADL)
Delayed: 8.46 +0.30 (3.68%)
Prev. Close $8.16  
Open$8.23 
52 Wk High$ 
52 Wk Low$ 
Day High$8.72 
Day Low$8.16 
P/E N/A  
EPS$ 
Volume1,000,814 

Friends, Peers and Foes (?): TRIN (more...)

Jun 2, 2026 08:05 AM Candel publishes phase 3 prostate cancer trial data in Lancet Oncology
Jun 2, 2026 08:05 AM Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Loca
Jun 1, 2026 04:05 PM Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026 03:22 PM Candel Therapeutics Inc. (CADL) PT Raised to $9 at BofA Securities
May 15, 2026 04:19 PM Form 8-K Candel Therapeutics, For: May 15
May 15, 2026 04:05 PM Candel Therapeutics reports extended clinical benefits in phase 3 prostate cancer trial
May 15, 2026 04:05 PM Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
May 15, 2026 08:09 AM Form SCHEDULE 13G Candel Therapeutics, Filed by: RTW INVESTMENTS, LP
May 14, 2026 08:31 AM Form 10-Q Candel Therapeutics, For: Mar 31
May 14, 2026 08:28 AM Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 20c
View All Articles

Entities mentioned with CADL

View All Entities